{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:43:44Z","timestamp":1775666624210,"version":"3.50.1"},"reference-count":20,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:p>There are several challenges that arise in caring for women with hereditary angioedema (HAE). Most notably, the disease course during pregnancy is unpredictable, but studies show that plasma-derived C1-inhibitor is effective and safe for treatment of attacks as well as long-term prophylaxis (LTP) in select patients. Vaginal deliveries are preferred to caesarean sections, and epidural anesthesia is preferred to general anesthesia in lowering the risk of an acute attack. Lactation postpartum may increase HAE attacks. With regard to contraception, combined oral contraceptive pills that contain estrogen exacerbate symptoms. Similarly, estrogen-replacement therapy in menopause may increase attacks and is contraindicated. Fertility is not impacted by HAE itself or by HAE medications. The risk of breast cancer and female reproductive cancer in women with HAE is comparable with that of the general population, but, in patients with HAE and breast cancer, LTP with androgens is contraindicated. Estrogen modulators, e.g., tamoxifen, should be used with caution. Here, we reviewed these special considerations and others that are vital to providers in caring for women with HAE.<\/jats:p>","DOI":"10.2500\/aap.2020.41.200077","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T04:41:14Z","timestamp":1603860074000},"page":"S47-S50","source":"Crossref","is-referenced-by-count":25,"title":["Hereditary angioedema: Special considerations in women"],"prefix":"10.2500","volume":"41","author":[{"given":"Elizabeth","family":"Yakaboski","sequence":"first","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Motazedi","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/whe.16.6","article-title":"Managing the female patient with hereditary angioedema","volume":"12","author":"Banerji","year":"2016","journal-title":"Womens Health (Lond)"},{"key":"B2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jaci.2011.11.025","article-title":"International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency","volume":"129","author":"Caballero","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"484.e1","DOI":"10.1016\/j.ajog.2008.04.034","article-title":"Disease expression in women with hereditary angioedema","volume":"199","author":"Bouillet","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cea.12055","article-title":"Benefits of progestin contraception in non-allergic angioedema","volume":"43","author":"Saule","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"B5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01526-7","article-title":"Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy","volume":"114","author":"Bork","year":"2003","journal-title":"Am J Med"},{"key":"B6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jaci.2009.03.038","article-title":"Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy","volume":"124","author":"Bork","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2500\/aap.2013.34.3645","article-title":"Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women","volume":"34","author":"Baker","year":"2013","journal-title":"Allergy Asthma Proc"},{"key":"B8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejogrb.2010.05.008","article-title":"The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey","volume":"152","author":"Czaller","year":"2010","journal-title":"Eur J Obstet Gynecol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"131.e1","DOI":"10.1016\/j.ajog.2010.03.003","article-title":"Characterization of acute hereditary angioedema attacks during pregnancy and breastfeeding and their treatment with C1 inhibitor concentrate","volume":"203","author":"Martinez-Saguer","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.jaip.2020.03.009","article-title":"Experience with intravenous plasma-derived C1-inhibitor in pregnant women with hereditary angioedema: a systematic literature review","volume":"8","author":"Brooks","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaip.2017.12.022","article-title":"Use of pdC1-INH concentrate for long term prophylaxis during pregnancy in hereditary angioedema with normal C1-INH","volume":"6","author":"Garcia","year":"2018","journal-title":"J Allergy Clin Immunology Pract"},{"key":"B12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.anai.2017.08.015","article-title":"Successful perinatal management of hereditary angioedema with normal C1 esterase inhibitor and factor XII mutation using C1 esterase inhibitor therapy","volume":"119","author":"Gibbons","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1016\/j.jaip.2019.05.042","article-title":"Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy","volume":"7","author":"Moldovan","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.anai.2018.09.104","article-title":"Experience with recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy","volume":"121","author":"Bernstein","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2500\/aap.2013.34.3635","article-title":"HAE update: special considerations in the female patient with hereditary angioedema","volume":"34","author":"Geng","year":"2013","journal-title":"Allergy Asthma Proc"},{"key":"B16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaip.2013.07.002","article-title":"US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency","volume":"1","author":"Zuraw","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.rbmo.2010.05.016","article-title":"Case report: first successful application of preimplantation genetic diagnosis for hereditary angioedema","volume":"21","author":"Bautista-Ll\u00e1cer","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"B18","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/bcr3117","article-title":"Premenopausal serum androgens and breast cancer risk: a nested case-control study","volume":"14","author":"Zeleniuch-Jacquotte","year":"2012","journal-title":"Breast Cancer Res"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(13)70301-2","article-title":"Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies","volume":"14","author":"Key","year":"2013","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/annonc\/mdp295","article-title":"Tamoxifen contraindicated in women with hereditary angioedema?","volume":"20","author":"Rousset-Jablonski","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2020\/00000041\/a00106s1\/art00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T23:44:42Z","timestamp":1618098282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2020.41.200077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["1088-5412(20201101)41:6+L.47;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2020.41.200077","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}